PRMT5 and glioblastoma: Six of the nine primary GBM cultures studied showed significant reduction in SFC upon treatment with both PRMT5 inhibitors, suggesting that PRMT5 inhibition limits the upfront clonogenic potential of the majority of fresh primary GBM cells (Fig. 1g and Supplementary Fig. 1f).